These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34591259)

  • 41. Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised controlled trial.
    Temple B; Toan NT; Dai VTT; Bright K; Licciardi PV; Marimla RA; Nguyen CD; Uyen DY; Balloch A; Huu TN; Mulholland EK
    Lancet Infect Dis; 2019 May; 19(5):497-509. PubMed ID: 30975525
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Validation of a Novel Forecasting Method for Estimating the Impact of Switching Pneumococcal Conjugate Programs: Evidence from Belgium.
    Wilson MR; McDade CL; Perdrizet JE; Mignon A; Farkouh RA; Wasserman MD
    Infect Dis Ther; 2021 Sep; 10(3):1765-1778. PubMed ID: 34250576
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
    Cho BH; Stoecker C; Link-Gelles R; Moore MR
    Vaccine; 2013 Dec; 31(50):6011-21. PubMed ID: 24148572
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Retrospective Impact Analysis and Cost-Effectiveness of the Pneumococcal Conjugate Vaccine Infant Program in Australia.
    Perdrizet J; Lai YS; Williams S; Struwig VA; Wasserman M
    Infect Dis Ther; 2021 Mar; 10(1):507-520. PubMed ID: 33575966
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea.
    Sohn HS; Suh DC; Jang E; Kwon JW
    J Manag Care Pharm; 2010; 16(1):32-45. PubMed ID: 20044845
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians.
    Dirmesropian S; Wood JG; MacIntyre CR; Beutels P; McIntyre P; Menzies R; Reyes JF; Chen C; Newall AT
    Vaccine; 2017 Aug; 35(34):4307-4314. PubMed ID: 28693751
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pneumococcal Conjugate Vaccine Impact on Serotype 3: A Review of Surveillance Data.
    Sings HL; Gessner BD; Wasserman MD; Jodar L
    Infect Dis Ther; 2021 Mar; 10(1):521-539. PubMed ID: 33587245
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Estimating the Cost-Effectiveness of Switching to Higher-Valency Pediatric Pneumococcal Conjugate Vaccines in the United Kingdom.
    Wilson M; Lucas A; Mendes D; Vyse A; Mikudina B; Czudek C; Ellsbury GF; Perdrizet J
    Vaccines (Basel); 2023 Jun; 11(7):. PubMed ID: 37514984
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-Effectiveness Analysis of Routine Use of 15-Valent Pneumococcal Conjugate Vaccine in the US Pediatric Population.
    Huang M; Hu T; Weaver J; Owusu-Edusei K; Elbasha E
    Vaccines (Basel); 2023 Jan; 11(1):. PubMed ID: 36679980
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the pediatric population in South Korea.
    Kang DW; June Choe Y; Lee JY; Suk IA; Kim YS; Kim HY; Byun BK; Park SK
    Vaccine; 2024 Jun; ():. PubMed ID: 38845302
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Choosing between 7-, 10- and 13-valent pneumococcal conjugate vaccines in childhood: a review of economic evaluations (2006-2014).
    Wu DB; Chaiyakunapruk N; Chong HY; Beutels P
    Vaccine; 2015 Mar; 33(14):1633-58. PubMed ID: 25681663
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study.
    Desmet S; Lagrou K; Wyndham-Thomas C; Braeye T; Verhaegen J; Maes P; Fieuws S; Peetermans WE; Blumental S
    Lancet Infect Dis; 2021 Jan; 21(1):127-136. PubMed ID: 32702303
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Invasive pneumococcal disease in Canada 2010-2017: The role of current and next-generation higher-valent pneumococcal conjugate vaccines.
    Dion SB; Major M; Gabriela Grajales A; Nepal RM; Cane A; Gessner B; Vojicic J; Suaya JA
    Vaccine; 2021 May; 39(22):3007-3017. PubMed ID: 33824041
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru.
    Gomez JA; Tirado JC; Navarro Rojas AA; Castrejon Alba MM; Topachevskyi O
    BMC Public Health; 2013 Oct; 13():1025. PubMed ID: 24171921
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness analysis of pediatric immunization program with 15-valent pneumococcal conjugate vaccine in Japan.
    Tajima A; Abe M; Weaver J; Huang M
    J Med Econ; 2023; 26(1):1034-1046. PubMed ID: 37555281
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand.
    Varghese L; Talbot L; Govender A; Zhang XH; Mungall BA
    Appl Health Econ Health Policy; 2018 Jun; 16(3):331-345. PubMed ID: 29633160
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness of using 2 vs 3 primary doses of 13-valent pneumococcal conjugate vaccine.
    Stoecker C; Hampton LM; Link-Gelles R; Messonnier ML; Zhou F; Moore MR
    Pediatrics; 2013 Aug; 132(2):e324-32. PubMed ID: 23821695
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-Effectiveness Analysis of Pneumococcal Vaccination with the Pneumococcal Polysaccharide NTHi Protein D Conjugate Vaccine in the Philippines.
    Zhang XH; Nievera MC; Carlos J; Lucero M; Bibera G; Atienza MI; Topachevskyi O; Navarro-Locsin CG
    Value Health Reg Issues; 2014 May; 3():156-166. PubMed ID: 29702921
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants.
    Rozenbaum MH; Huang L; Perdrizet J; Cane A; Arguedas A; Hayford K; Tort MJ; Chapman R; Dillon-Murphy D; Snow V; Chilson E; Farkouh RA
    Vaccine; 2024 Jan; 42(3):573-582. PubMed ID: 38191278
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Seven Chinese Cities.
    Li Y; Wang H; Furnback W; Wang BCM; Zhu S; Dong P
    Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835299
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.